Literature DB >> 29606164

Accuracy of composite diagnostic standards for pneumococcal pneumonia in vaccine trials.

M Suzuki1, S Katoh1, R Miyahara1, K Ariyoshi1, K Morimoto1.   

Abstract

Because of a lack of gold standard diagnostics, a combination of multiple diagnostic tests, or composite diagnostic standard, has been used to measure pneumococcal pneumonia (PP) in pneumococcal vaccine trials. We estimated the accuracy of composite diagnostic standards for PP used in previous randomised controlled trials by simple formulas. A systematic literature review identified five eligible trials and all trials had used different combinations of diagnostic tests for PP. The estimated values of sensitivity and minimum specificity of composite diagnostic standards varied substantially between trials: 48.4% to 98.1% and 71.0% to 97.3%, respectively. Without standardizing the outcome measurements, pneumococcal vaccine efficacy estimates against PP are not comparable between trials and their pooled estimates are biased.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29606164      PMCID: PMC9134358          DOI: 10.1017/S0950268818000651

Source DB:  PubMed          Journal:  Epidemiol Infect        ISSN: 0950-2688            Impact factor:   4.434


  31 in total

1.  Classical and latent class analysis evaluation of sputum polymerase chain reaction and urine antigen testing for diagnosis of pneumococcal pneumonia in adults.

Authors:  Jay C Butler; Stephen C Bosshardt; Maureen Phelan; Shannon M Moroney; M Lucia Tondella; Monica M Farley; Anne Schuchat; Barry S Fields
Journal:  J Infect Dis       Date:  2003-04-09       Impact factor: 5.226

2.  Value of composite reference standards in diagnostic research.

Authors:  Christiana A Naaktgeboren; Loes C M Bertens; Maarten van Smeden; Joris A H de Groot; Karel G M Moons; Johannes B Reitsma
Journal:  BMJ       Date:  2013-10-25

3.  Measurement of antibody responses to pneumolysin--a promising method for the presumptive aetiological diagnosis of pneumococcal pneumonia.

Authors:  E Jalonen; J C Paton; M Koskela; Y Kerttula; M Leinonen
Journal:  J Infect       Date:  1989-09       Impact factor: 6.072

4.  Serotype-specific effectiveness of 23-valent pneumococcal polysaccharide vaccine against pneumococcal pneumonia in adults aged 65 years or older: a multicentre, prospective, test-negative design study.

Authors:  Motoi Suzuki; Bhim Gopal Dhoubhadel; Tomoko Ishifuji; Michio Yasunami; Makito Yaegashi; Norichika Asoh; Masayuki Ishida; Sugihiro Hamaguchi; Masahiro Aoshima; Koya Ariyoshi; Konosuke Morimoto
Journal:  Lancet Infect Dis       Date:  2017-01-24       Impact factor: 25.071

5.  Clinical efficacy of anti-pneumococcal vaccination in patients with COPD.

Authors:  I Alfageme; R Vazquez; N Reyes; J Muñoz; A Fernández; M Hernandez; M Merino; J Perez; J Lima
Journal:  Thorax       Date:  2005-10-14       Impact factor: 9.139

6.  Validation of an immunodiagnostic assay for detection of 13 Streptococcus pneumoniae serotype-specific polysaccharides in human urine.

Authors:  Michael W Pride; Susanne M Huijts; Kangjian Wu; Victor Souza; Sherry Passador; Chunyan Tinder; Esther Song; Arik Elfassy; Lisa McNeil; Ronald Menton; Roger French; Janice Callahan; Chris Webber; William C Gruber; Marc J M Bonten; Kathrin U Jansen
Journal:  Clin Vaccine Immunol       Date:  2012-06-06

7.  Immunisation with a polyvalent pneumococcal vaccine. Reduction of adult respiratory mortality in a New Guinea Highlands community.

Authors:  I D Riley; P I Tarr; M Andrews; M Pfeiffer; R Howard; P Challands; G Jennison
Journal:  Lancet       Date:  1977-06-25       Impact factor: 79.321

Review 8.  Definition, reporting, and interpretation of composite outcomes in clinical trials: systematic review.

Authors:  Gloria Cordoba; Lisa Schwartz; Steven Woloshin; Harold Bae; Peter C Gøtzsche
Journal:  BMJ       Date:  2010-08-18

9.  The 23-valent pneumococcal polysaccharide vaccine in patients with rheumatoid arthritis: a double-blinded, randomized, placebo-controlled trial.

Authors:  Yasumori Izumi; Manabu Akazawa; Yukihiro Akeda; Shigeto Tohma; Fuminori Hirano; Haruko Ideguchi; Ryutaro Matsumura; Tomoya Miyamura; Shunsuke Mori; Takahiro Fukui; Nozomi Iwanaga; Yuka Jiuchi; Hideko Kozuru; Hiroshi Tsutani; Kouichirou Saisyo; Takao Sugiyama; Yasuo Suenaga; Yasumasa Okada; Masao Katayama; Kenji Ichikawa; Hiroshi Furukawa; Kenji Kawakami; Kazunori Oishi; Kiyoshi Migita
Journal:  Arthritis Res Ther       Date:  2017-01-25       Impact factor: 5.156

Review 10.  Effectiveness of the 23-Valent Pneumococcal Polysaccharide Vaccine (PPV23) against Pneumococcal Disease in the Elderly: Systematic Review and Meta-Analysis.

Authors:  Gerhard Falkenhorst; Cornelius Remschmidt; Thomas Harder; Eva Hummers-Pradier; Ole Wichmann; Christian Bogdan
Journal:  PLoS One       Date:  2017-01-06       Impact factor: 3.240

View more
  1 in total

Review 1.  PCV13 Vaccination of Adults against Pneumococcal Disease: What We Have Learned from the Community-Acquired Pneumonia Immunization Trial in Adults (CAPiTA).

Authors:  Christian Theilacker; Mark A Fletcher; Luis Jodar; Bradford D Gessner
Journal:  Microorganisms       Date:  2022-01-08
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.